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Aim To analyze potential and actual drug-drug interac-
tions reported to the Spontaneous Reporting Database of 
the Croatian Agency for Medicinal Products and Medical 
Devices (HALMED) and determine their incidence.
Methods  In  this  retrospective  observational  study  per-
formed from March 2005 to December 2008, we detected 
potential and actual drug-drug interactions using interac-
tion programs and analyzed them.
Results HALMED received 1209 reports involving at least 
two drugs. There were 468 (38.7%) reports on potential 
drug-drug interactions, 94 of which (7.8% of total reports) 
were actual drug-drug interactions. Among actual drug-
drug interaction reports, the proportion of serious adverse 
drug reactions (53 out of 94) and the number of drugs 
(n = 4) was significantly higher (P < 0.001) than among the 
remaining reports (580 out of 1982; n = 2, respectively). Ac-
tual drug-drug interactions most frequently involved ner-
vous system agents (34.0%), and interactions caused by 
antiplatelet, anticoagulant, and non-steroidal anti-inflam-
matory drugs were in most cases serious. In only 12 out of 
94 reports, actual drug-drug interactions were recognized 
by the reporter.
Conclusion The study confirmed that the Spontaneous 
Reporting Database was a valuable resource for detecting 
actual drug-drug interactions. Also, it identified drugs lead-
ing to serious adverse drug reactions and deaths, thus in-
dicating the areas which should be in the focus of health 
care education.
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Adverse  drug  reactions  (ADR)  are  among  the  leading 
causes of mortality and morbidity responsible for causing 
additional complications (1,2) and longer hospital stays. 
Magnitude of ADRs and the burden they place on health 
care system are considerable (3-6) yet preventable public 
health problems (7) if we take into consideration that an 
important cause of ADRs are drug-drug interactions (8,9). 
Although there is a substantial body of literature on ADRs 
caused by drug-drug interactions, it is difficult to accu-
rately estimate their incidence, mainly because of different 
study designs, populations, frequency measures, and clas-
sification systems (10-15).
Many studies including different groups of patients found 
the percentage of potential drug-drug interactions result-
ing in ADRs to be from 0%-60% (10,11,16-25). System analy-
sis of ADRs showed that drug-drug interactions represented 
3%-5% of all in-hospital medication errors (3). The most en-
dangered groups were elderly and polimedicated patients 
(22,26-28), and emergency department visits were a frequent 
result (29). Although the overall incidence of ADRs caused by 
drug-drug interactions is modest (11-13,15,29,30), they are 
severe and in most cases lead to hospitalization (31,32).
Potential drug-drug interactions are defined on the basis 
of on retrospective chart reviews and actual drug-drug 
interactions are defined on the basis of clinical evidence, 
ie, they are confirmed by laboratory tests or symptoms 
(33). The frequency of potential interactions is higher than 
that of actual interactions, resulting in large discrepancies 
among study findings (24).
A valuable resource for detecting drug-drug interactions is 
a spontaneous reporting database (15,34). It currently uses 
several methods to detect possible drug-drug interactions 
(15,29,35,36). However, drug-drug interactions in general 
are rarely reported and information about the ADRs due to 
drug-drug interactions is usually lacking.
The aim of this study was to estimate the incidence of actual 
and potential drug-drug interactions in the national Sponta-
neous Reporting Database of ADRs in Croatia. Additionally, 
we assessed the clinical significance and seriousness of drug-
drug interactions and their probable mechanism of action.
MeThoDS
Data source
A retrospective observational study was performed from 
March 2005 to December 2008. Data were obtained from 
the  Spontaneous  Reporting  Database  of  Pharmacovigi-
lance Department of the Croatian Agency for Medicinal 
Products  and  Medical  Devices  (HALMED).  Spontaneous 
Reporting Database uses VigiFlow, web-based Individual 
Case Safety Report management system that is specially 
designed for use by national centers in the World Health 
Organization  Programme  for  International  Drug  Moni-
toring. Data elements for transmission of individual case 
safety reports are entered according to standardized ICH 
E2B format (International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use) (37).
ADR reporting is a legal obligation of every health care pro-
fessional in Croatia, and patients are free to report as well 
(38,39). Reports are made in writing and sent by land mail, 
fax, or electronic mail using a prescribed form. Reporters 
are classified into the following groups: primary care physi-
cians, secondary and tertiary care physicians, pharmacists, 
and patients. Drugs are grouped according to the Anatom-
ical-Therapeutic-Chemical drug classification (ATC) and en-
tered into the spontaneous reporting database. One report 
can describe one or more ADRs.
Data concerning the suspected ADRs were coded into the 
related Preferred Term and System Organ Class using the 
Medical Dictionary for Drug Regulatory Affairs (MedDRA) 
adverse drug reaction terminology (40).
Data analysis
ADR reports were considered only if pharmacovigilance 
assessors evaluated the relatedness to the use of the sus-
pected drug as possible, probable, or certain (41). We an-
alyzed all reports involving at least two drugs suspected 
of causing an ADR. Drug-drug interactions were detected 
with online version of computerized interaction detection 
system Drug-Reax (42). To confirm Drug Reax results, we 
used online version of Stockley drug interaction program 
(43) and literature search of Medline.
For each report containing a potential drug-drug interac-
tion, we verified if the description of the ADR corresponded 
to the interaction effect described in drug interaction pro-
grams and if it did it was considered actual (eg, first-dose 
hypotension of ACE inhibitors in patients receiving long-
term treatment with ACE inhibitors and diuretics). Evalua-
tion was made by a panel of five experts, including a phar-
macist, clinical pharmacist, two physicians, and a clinical 
pharmacologist. They reviewed all the available infor-CLINICAL SCIENCES 606 Croat Med J. 2011; 52: 604-14
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mation in the reports, and when necessary, the reporter was 
contacted for follow-up information. ADRs were considered 
serious if they resulted in one of the following outcomes ac-
cording to the ICH E 2A (44) guidelines: death, life threat-
ening condition, inpatient hospitalization, or prolongation 
of existing hospitalization, persistent or significant disabil-
ity/incapacity, a congenital anomaly/birth defect, or other 
important medical event according to CIOMS V (Council 
for International Organizations of Medical Sciences, 2001) 
(45). Data were analyzed in respect to the total number of 
reports, demographic characteristics of the patients, clas-
sification of suspected drugs, System Organ Class, serious-
ness, and the source of reports. Medians (ranges) and per-
centages were used to present the data. ADR reports caused 
by actual drug-drug interactions were compared with ADR 
reports not caused by actual drug-drug interactions. The 
results were analyzed using the Mann-Whitney and χ2 test. 
Data analysis was done by the Predictive Analytics Software, 
version 18.0 (SPSS Inc., Chicago, IL, USA).
ReSulTS
Incidence of drug-drug interactions
From March 2005 to December 2008, HALMED received 
2076 reports of ADRs, 1209 of which (58.2%) involved more 
than one drug. In 94 (7.8%) of these, ADRs were caused by 
actual drug-drug interactions, with 106 different pairs of 
concomitantly administered drugs. In 83 reports (88.3%), 
ADRs were caused by only one drug-drug interaction, in 10 
reports (10.6%) by 2 drug-drug interactions, and in 1 report 
(1.1%) by 3 drug-drug interactions.
Potential drug-drug interactions were identified in 468 of 
1209 reports (38.7%) involving more than one drug, and 
actual drug-drug interactions in 94 reports (20.8% of po-
tential drug-drug interactions).
Characteristics of actual drug-drug interactions
In  94  reports  of  actual  drug-drug  interactions,  the  age 
range of patients was 3 days-85 years (median 58 years). 
In 14 cases, patients were less than thirty years old, and all 
interacting drugs prescribed to them belonged to nervous 
system medications. On average, they were taking 4 medi-
cations, ranging from 2 to 12. Fifty-three patients were fe-
male and 41 were male.
Most ADRs belonged to the following System Organ 
Classes:  gastrointestinal  disorders  (24.3%),  nervous 
system disorders (14.5%), investigations (11.8%), and psy-
chiatric disorders (11.2%) (Table 1). Most frequently report-
ed MedRA Preferred Terms of drug-drug interactions were 
gastro-intestinal tract hemorrhage and muscular disorders.
Fifty-three out of 94 ADR reports (56.4%) caused by actual 
drug-drug interactions were serious, 2 of which were fa-
tal (3.8%), 12 were life threatening (22.6%), 23 led to hos-
pitalization  (43.4%),  and  16  were  serious  according  to 
the CIOMS V criteria (30.2%). Fatal cases were 69-year old 
woman who died from stomach and duodenal perforation 
due to additive gastrointestinal toxicity of amlodipine and 
indometacin and a 55-year old man who died from pan-
cytopenia and sepsis developed from fluorouracil toxicity 
caused  by  concomitantly  administered  fluorouracil  and 
leucovorin.
Drugs most frequently involved in actual drug-drug 
interactions
The most frequent drugs involved in actual drug-drug in-
teractions were cyclosporine (n = 15), warfarin (n = 9), and 
TaBle 1. Distribution of adverse drug reactions (aDR) caused 
and not caused by actual drug-drug interactions (DDI) classi-
fied by Medical Dictionary for Drug Regulatory affairs System 
organ Class (MedDRa SoC) (40)
No. (%) of aDRs
MedDRa SoC
caused by 
actual DDIs*
not caused 
by DDIs†
Gastrointestinal disorders 37 (24.3) 625 (21.3)
Nervous system disorders 22 (14.5) 325 (11.1)
Investigations 18 (11.8)   96 (3.3)
Psychiatric disorders 17 (11.2) 123 (4.2)
General disorders and administration 
site conditions
16 (10.5) 324 (11.0)
Skin and subcutaneous tissue disorders 10 (6.6) 625 (21.3)
Blood and lymphatic system disorders   9 (5.9)   62 (2.1)
Muscle disorders   9 (5.9) 111 (3.8)
Vascular disorders   4 (2.6)   27 (0.9)
Respiratory, thoracic, and mediastinal 
disorders
  2 (1.3) 187 (6.4)
Metabolism and nutrition disorders   2 (1.3)   37 (1.3)
Cardiac disorders   2 (1.3)   50 (1.7)
Reproductive system and breast 
disorders
  1 (0.7)   43 (1.5)
Eye disorders   1 (0.7) 103 (3.5)
Renal and urinary disorders   1 (0.7)   42 (1.4)
Infections and infestations   1 (0.7)   22 (0.7)
Other  / 132 (4.5)
*94 reports contained 152 adverse drug reactions.
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fluvastatin (n = 8) (Table 2). According to the ATC classifica-
tion, the drugs involved in 34.0% of actual drug-drug inter-
actions were nervous system medications (ATC group N). 
In most of these interactions, both interacting drugs be-
longed to nervous system medications (33 out of 39) and 
the most frequently interacting drug was paroxetine (Ta-
ble 2). Interaction between lamotrigine and valproic acid 
caused serious rash with systematic involvement in one 
young man (23 years), two girls (4 and 14 years, respec-
tively), and one boy (16 years) (Table 2).
Twenty-seven percent of actual drug-drug interactions in-
volved cardiovascular system medications (ATC group C). In 
most cases, the other interacting drug did not belong to the 
ATC group C (21 out of 35). We detected 16 drug-drug in-
teractions involving hydroxymethylglutaryl-CoA reductase 
inhibitors (statins), 8 of which were caused by fluvastatin, 
and 4 drug-drug interactions involving simvastatin and ator-
vastatin each. The most frequent actual interaction was be-
tween fluvastatin and cyclosporine (n = 6) (Table 2).
There were 12.3% of actual drug-drug interactions that 
involved  drugs  belonging  to  antineoplastic  and  immu-
nomodulating medications (ATC group L). Most of them 
involved cyclosporine (15 out of 21) (Table 2). Two cases 
of actual interactions involved methotrexate and non-ste-
roidal anti-inflammatory drugs (ibuprofen, tenoxicam) and 
one involved methotrexate and omeprazole. The mecha-
nism of these interactions involved decreased methotrex-
ate clearance.
There were 10.9% of actual drug-drug interactions that in-
volved medications affecting blood and blood forming or-
gans (ATC group B), and more than half of the cases (9 out 
of 17) involved warfarin (Table 2). The most frequently re-
ported actual drug-drug interaction in this group was be-
tween acetylsalicylic acid and clopidogrel (n = 3) (Table 2).
There were 15.8% of actual drug-drug interactions that in-
volved  drugs  belonging  to  the  musculo-skeletal  system 
(ATC group M), alimentary tract, and metabolism (ATC group 
A), anti-infectives for systemic use (ATC group J), systemic 
hormonal preparations, excluding sex hormones and insu-
lins, genito-urinary system and sex hormones (ATC group 
H), genito-urinary system and sex hormones (ATC group G), 
and various medicines group (ATC group V) (Figure 1).
Most actual drug interactions involved pharmacokinetic 
interactions (44.3%), 32.1% involved pharmacodynamic in-
teractions, and 3.8% involved both pharmacokinetic and 
pharmacodynamic interactions. In 19.8% of actual drug-
drug interactions, the mechanism was unknown. The pro-
portion of serious cases caused by actual drug-drug inter-
actions was highest in the following ATC groups: H and V, B, 
and J and M (Figure 2), and lowest in H ATC group (5 drugs) 
and V ATC group (2 drugs).
Figure 1.
Distribution of suspected drugs according to anatomical-Therapeutic-Chemical (aTC) drug 
classification in the group of adverse drug reaction reports not caused by drug-drug interac-
tions (open bars) and the group of adverse drug reaction reports caused by drug-drug inter-
actions (closed bars). aTC groups: a – alimentary Tract and Metabolism; B – Blood and Blood 
Forming organs; C – Cardiovascular System Drugs; D – Dermatologicals; G – Genito urinary 
System and Sex hormones; h – Systemic hormonal Preparations, excluding Sex hormones 
and Insulins, Genito urinary System and Sex hormones; J – antiinfectives for Systemic use; l 
– antineoplastic and Immunomodulating Medications; M – Musculo-Skeletal System; N – Ner-
vous System; P – antiparasitic Products, Insecticides and Repellents; R – Respiratory System; 
S – Sensory organs; V – Various.
Figure 2.
Distribution of serious (closed bars) and not serious (open bars) cases of actual drug-drug in-
teractions in different anatomical-Therapeutic-Chemical (aTC) drug classification groups. aTC 
groups: a – alimentary Tract and Metabolism; B – Blood and Blood Forming organs; C – Car-
diovascular System Drugs; G – Genito urinary System and Sex hormones; h – Systemic hor-
monal Preparations, excluding Sex hormones and Insulins, Genito urinary System and Sex 
hormones; J – anti-infectives for Systemic use; l – antineoplastic and Immunomodulating 
Medications; M – Musculo-Skeletal System; N – Nervous System; V – Various.CLINICAL SCIENCES 608 Croat Med J. 2011; 52: 604-14
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TaBle 2. Drugs most frequently involved in actual drug-drug interactions (DDI)*
Drug (number of 
DDIs*)
Drug pairs 
(number of DDI combinations)
Most relevant 
reported aDRs Mechanism of interaction
Cyclosporine (15) cyclosporine - fluvastatin (6) rhabdomyolysis, 
myopathy
inhibition of fluvastatin metabolism
cyclosporine- amlodipine (3) cyclosporine toxicity inhibition of cyclosporine metabolism by amlodipine
cyclosporine – methylprednisolone (2) cyclosporine toxicity decreased metabolism of cyclosporine
cyclosporine – prednisone (1) cyclosporine toxicity decreased metabolism of cyclosporine
cyclosporine- carvedilol (1) cyclosporine toxicity inhibition of cyclosporine metabolism
cyclosporine- simvastatin (1) rhabdomyolysis inhibition of cytochrome P450-mediated metabolism 
of simvastatin and transporters
cyclosporine- ciprofloxacin (1) cyclosporine toxicity decreased cyclosporine metabolism; pharmacody-
namic antagonism
Warfarin (9) warfarin-enoxaparin (2) bleeding additive anticoagulation
warfarin- acetaminophen (1) bleeding inhibition of warfarin metabolism or interference with 
clotting factor formation
warfarin -allopurinol (1) bleeding inhibition of warfarin metabolism
warfarin-amoxicillin (1) increased INR unknown
warfarin-atenolol (1) increased INR unknown
warfarin-fluvastatin (1) INR increased and 
bleeding
inhibition of warfarin metabolism
warfarin- methylprednisolone (1) anemia unknown
warfarin-simvastatin (1) myalgia competition for cytochrome P450 3A4-mediated 
metabolism
Fluvastatin (8) fluvastatin -cyclosporine (6) see above
fluvastatin -diclophenac (1) gastrointestinal toxicity inhibition of diclophenac metabolism
fluvastatin -warfarin (1) see above
Paroxetine (8) paroxetine - risperidone (4) extrapyramidal ADRs, 
weight increase
concomitant use of paroxetine (potent CYP2D6 inhibi-
tor) and risperidone (CYP2D6 substrate) has resulted in 
increased risperidone plasma concentrations and an 
increased risk of risperidone adverse effects.
paroxetine - clozapine (1) sedation, hypotension decreased clozapine metabolism
paroxetine- fluphenazine (1) extrapyramidal ADRs inhibition of cytochrome P450-mediated fluphenazine 
metabolism by paroxetine
paroxetine-meloxicam (1) hematochezia At therapeutic doses SSRIs can block this reuptake of 
serotonin by platelets, leading to serotonin depletion, 
impairment of hemostatic function and increase the 
risk of bleeding
paroxetine - tramadol (1) palpitations, headache, 
dizziness
increased concentration of serotonin in the nervous 
system and periphery; inhibition of the CYP2D6-medi-
ated formation of tramadol active metabolites (-)-M1 
and (+)-M1 by paroxetine
Risperidone (7) risperidone- paroxetine (4) see above see above
risperidone- clozapine (1) incontinence of urine compete for metabolism by the cytochrome P450 
isoenzyme CYP2D6 resulting in a reduction in the 
metabolism of the clozapine
risperidone - haloperidol (1) QT prolongation additive effects on QT prolongation
risperidone - quetiapine (1) neuroleptic malignant 
syndrome
additive effects
sertraline (5) sertraline - alprazolam (1) neonatal respiratory 
distress syndrome
inhibition of cytochrome P450 3A-mediated alprazo-
lam metabolism609 Mirošević Skvrce et al: Adverse drug reactions caused by drug-drug interactions 
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In 7 out of 94 ADR reports caused by actual drug-drug 
interactions, at least one of the interacting drugs was an 
over-the-counter drug. In 6 cases, it was acetylsalicylic acid 
and in 2 cases ranitidine. Moreover, 6 out of 7 ADRs involv-
ing over-the-counter drugs were serious. Two additional 
serious ADR cases involved drugs administered in the dose 
registered as over-the-counter (eg, ibuprofen 400 mg and 
omeprazole 10 mg).
Reporters of adverse drug reactions involving actual 
drug-drug interactions
ADRs caused by actual drug-drug interactions were in most 
cases reported by secondary and tertiary care physicians 
and ADRs not caused by actual drug-drug interactions by 
primary care physicians (Figure 3). The most serious ADR re-
ports caused by actual drug-drug interaction were detected 
by secondary and tertiary care physicians (33 reports).
Actual drug-drug interactions were recognized by the re-
porter himself or herself in only 12 out of 94 reports. In the 
remaining reports, the reporter either did not state whether 
both interacting drugs were the suspected drugs or the box 
“ADR caused by drug-drug interaction” was not ticked. Re-
porters most frequently recognized actual drug-drug inter-
actions in which one of the drugs was an anticoagulant/anti-
platelet and least frequently drug-drug interactions in which 
one of the drugs was a psychiatric drug (only one case).
Comparison of reports of adverse drug reactions 
caused and not caused by actual drug- drug 
interactions
The number of serious reports (53 out of 94) and the num-
ber of drugs (median 4, range 2-12) in therapy was signifi-
cantly higher in the group of ADR reports caused by actual 
drug-drug interactions (P < 0.001) than among all other re-
ports (580 out of 1982; median 2, range 1-14, respectively).
These groups did not differ significantly in sex distribution 
or patient age (Table 3), but did differ in the distribution 
of the most frequently reported ADRs according to Med-
DRA System Organ Class (Table 1). The greatest difference 
between ADR reports caused by actual drug-drug interac-
tions and all other reports was observed in the following 
System Organ Classes: skin and subcutaneous tissue dis-
orders (6.6% vs 21.3%), investigations (11.8% vs 3.3%), psy-
chiatric disorders (11.2% vs 4.2%), blood and lymphatic sys-
tem disorders (5.9% vs 2.1%), and respiratory, thoracic and 
mediastinal disorders (1.3% vs 6.4%) (Table 1).
These two groups also differed according to the distribu-
tion of the most frequently suspected drugs according 
to ATC classification (Figure 1), and a significant dif-
sertraline - amitriptyline (1) sedation inhibition of amitriptyline metabolism
sertraline -lithium (1) nausea and vomiting additive effect
sertraline - olanzapine (1) weight increased inhibition of olanzapine mechanism
sertraline - zolpidem (1) hallucinations unknown
Valproic acid (5) valproic acid- lamotrigine (4) life-threatening rashes decreased lamotrigine metabolism
valproic acid - amitriptyline (1) disorientation, amnesia, 
hallucinations
decreased amitriptyline plasma clearance
Acetylsalicylic 
acid (5)
acetylsalicylic acid -clopidogrel (3) bleeding inhibition of platelet aggregation
acetylsalicylic acid -enoxaparin (1) bleeding decreased platelet function; decreased coagulation
acetylsalicylic acid - ketoprofen (1) gastrointestinal toxicity additive gastrointestinal irritation
*abbreviations: INR – International Normalized Ratio; SSRI – Selective Serotonin Reuptake Inhibitors; aDR – adverse drug reaction.
TaBle 2. Continued. Drugs most frequently involved in actual drug-drug interactions (DDI)*
Drug (number of 
DDIs*)
Drug pairs 
(number of DDI combinations)
Most relevant 
reported aDRs Mechanism of interaction
Figure 3.
Distribution of reporters in the group of adverse drug reaction reports caused by drug-drug 
interactions (closed bars) and the group of adverse drug reaction reports not caused by drug-
drug interactions (open bars).CLINICAL SCIENCES 610 Croat Med J. 2011; 52: 604-14
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ference was found for ATC groups J (P < 0.001), L (P < 0.001), 
B (P < 0.001), N (P = 0.009), R (P = 0.013), A (P = 0.025), and H 
(P = 0.029). The percentage of drugs belonging to N, L, B, 
and H ATC group was significantly higher in the group of 
actual drug-drug interactions reports (Figure 1).
DISCuSSIoN
Our study confirmed that the Spontaneous Reporting Da-
tabase was a valuable resource for detecting ADRs caused 
by drug-drug interactions and the drugs leading to serious 
ADRs and deaths, thus emphasizing the areas that should 
be in the focus of health care education. Most of the stud-
ies investigating ADRs associated with drug-drug interac-
tions were set in either hospital (3,10,29,46,47) or general 
practice setting (14,18,45-49). There was only a single study 
with the same methodology as ours. Leone et al (15) an-
alyzed Italian spontaneous reporting database and con-
cluded that it can be an important resource for detecting 
ADRs associated with the concomitant use of interacting 
drugs. Similar to us, they used all the cases that Drug Reax 
evaluated as possibly, probably, or certainly related to the 
use of suspected drugs (15).
The  methodology  of  detecting  drug-drug  interactions 
may be a limitation of our study, since at the time of 
analysis not all drug-drug interactions were known and 
drug-drug interactions clinically unimportant for the 
majority of patients can be consequential for the individ-
ual with decreased enzyme activity. Further limitations in-
clude under-reporting of ADRs, and reports with missing 
information on concomitant drugs and comorbidities due 
to retrospective study design. According to some studies, 
fewer than 6% of all ADRs are reported (50). An addition-
al limitation of our study could be the lack of denomina-
tor data such as the user population. Compared to other 
methodologies, we used more than one source of drug 
interaction-checking methods (43), which made our drug-
drug interaction detection more sensitive, thus minimiz-
ing the possibility of unrecognized drug interactions. Also, 
consensus between experts was reached in all cases.
The percentage of reports involving actual drug-drug in-
teractions was almost double in the Croatian than in Italian 
spontaneous reporting database (15). Probably because 
60.9% of reports in the Italian database involved only one 
suspected drug without concomitant therapy, while in our 
study this figure was considerably lower (41.8%). The two 
studies showed no significant difference in the frequency 
of ADR reports caused by actual drug-drug interactions in-
volving at least two drugs (P = 0.1446). However, our study 
had higher percentage of detected reports of actual drug-
drug interactions, which could be explained by previously 
mentioned  additional  drug  interaction-checking  meth-
ods. Vonbach et al (51) placed Drug-Reax among the top 
four drug-drug interaction screening software programs, 
with 0.98 specificity and 0.71 sensitivity when compared 
with Stockley’s Drug Interactions, which is used as gold 
standard.  Accordingly,  our  study  had  significantly  high-
er percentage of reports involving at least one potential 
drug-drug interaction than the study by Leone et al (15). 
It had a comparable proportion of actual among potential 
drug-drug interactions (20.8%) with the study by Leone et 
al (21.7%) (15), as well as with studies conducted in hospi-
tal settings (14.0%) (52) and among geriatric outpatients 
(25.5%) (53). These findings strongly confirm that drug-
drug  interactions  represent  an  important  and  frequent 
problem in clinical practice.
Variables  such  as  age,  polimedication,  and  the  state 
of  disease  increase  the  probability  of  an  interaction 
(16,22,33,54,55). The  percentage  of  serious  ADR  reports 
and the number of drugs in our study was higher in re-
ports on actual drug-drug interactions than among the re-
maining reports (15,29,56). Lin Chen-Fang et al (54) found 
that  the  prevalence  of  potential  drug-drug  interactions 
increased in a linear mode with increasing age and with 
the number of prescribed drugs (55). Furthermore, these 
TaBle 3. Comparison of adverse drug reaction (aDR) reports 
caused and not caused by actual drug-drug interactions (DDI)
Median (range) or number 
(%) of aDR reports*
Characteristic
not caused 
by DDIs
caused by 
DDIs P
Number of drugs prescribed 2 (1-14) 4 (2-12) <0.001
Patient age 55 y (1 days-
93 years)
58 y (3 days-
85 years)
  0.115
Patients’ sex:
female 1270 (64.1) 53 (56.4)   0.535
male 712 (35.9) 41 (43.6)
Seriousness of aDR:*
serious 580 (29.3) 53 (56.4) <0.001
not serious 1402 (70.7) 41 (43.6)
*Serious adverse drug reactions were those that resulted in the fol-
lowing outcomes according to the ICh e 2a (International Conference 
on harmonization of Technical Requirements for Registration of 
Pharmaceuticals for human use) guideline (44): death, life threatening 
condition, inpatient hospitalization or prolongation of existing hospi-
talization, persistent or significant disability/incapacity, a congenital 
anomaly/birth defect, or other important medical event according to 
CIoMS V (Council for International organizations of Medical Sciences 
2001).611 Mirošević Skvrce et al: Adverse drug reactions caused by drug-drug interactions 
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two factors interacted to increase the risk (54). However, 
we did not find any significant age difference between the 
patients experiencing ADRs caused by actual drug-drug 
interactions and those experiencing ADRs not caused by 
actual drug-drug interactions. This could be explained by 
the difference in the drugs involved; more than a third of 
actual drug-drug interactions in our study were caused by 
nervous system medications (especially paroxetine, risperi-
don, valproic acid, and lamotrigine), which are more fre-
quently used by younger patients than other ATC groups. 
Since nervous system medications were most frequently 
involved in actual drug-drug interactions and hardly ever 
recognized by the reporter, we identified a special need for 
alertness in this drug area.
The drug most frequently involved in actual drug-drug in-
teractions in our study was cyclosporine, while in the study 
by Leone et al it was the combination of digoxin and di-
uretics (15). Cyclosporine has been particularly hazardous 
in  transplant  patients  who  often  require  lipid-lowering 
therapy (57,58). Co-administration of these two types of 
drugs requires great caution since it can result in serious 
ADRs including rhabdomyolysis, as has been previously re-
ported by our research group (59).
Serious drug-drug interactions frequently involved anti-
platelet (60), anticoagulant (56), and non-steroidal anti-
inflammatory drugs (27,53,61,62) that caused gastroin-
testinal disorders. It is essential that health care providers 
recognize potentially interacting drug pairs in order to 
reduce the risk of drug-drug interactions and associated 
drug-related morbidity and mortality. In our study, re-
porters less frequently recognized actual drug-drug in-
teractions, which could be a consequence of restricted 
access to available drug interaction databases or alert-
ing drug-interaction systems and their limited availabil-
ity. Reporters most frequently recognized drug interac-
tions including anticoagulant and antiplatelet drugs and 
least frequently those including psychiatric drugs. This 
finding was also confirmed by Leone et al (15). Our re-
sults supported the findings of previous studies on the 
importance of prescribing-support systems and the need 
for additional education of health care providers in this 
area (63).
The main reporters of ADRs caused by actual drug-drug 
interactions were secondary and tertiary care physicians, 
while the main reporters of all ADRs were primary care 
physicians. This shows that most drug-drug interactions 
occur in hospital settings or that ADRs caused by actual 
drug-drug interactions are serious and more frequently re-
quire hospitalization.
The number of over-the-counter drugs involved in ADRs 
caused  by  actual  drug-drug  interactions  was  relative-
ly high considering the fact that over-the-counter drugs 
should have a good safety profile. Therefore, pharmacists, 
as the main dispensers, should be specially alerted about 
potential clinically relevant interactions.
In conclusion, the Spontaneous Reporting Database was 
a valuable resource for detecting ADRs associated with 
drug-drug  interactions.  We  obtained  clinical  evidence 
about ADRs associated with actual drug-drug interactions 
relevant for clinical practice, which involved nervous sys-
tem medications (ATC group N), antiplatelet, anticoagu-
lant, and non-steroidal anti-inflammatory drugs (in most 
serious cases of ADRs). Our findings confirm that ADR re-
ports caused by actual drug-drug interactions are more 
serious and frequently require hospitalization. Therefore, it 
is essential to introduce prescribing-support systems and 
additional education of health care professionals.
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